[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Sixth communication: Results of compatibility of CN 3123 (author's transl)].

1. During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) side-effects were reported in only 56 (=4.1%) of the 1371 patients who took part. 2. The numerous laboratory parameters studied in the whole group and in the group which received long-term treatment did not show any significant changes due to CN 3123. 3. The frequency and the type of side-effects which occurred under the combined preparation CN 3123 were the same as those known to be caused by sulfonamide treatment. 4. The good tolerance, which is a familial feature of sulfonamide treatment, is not impaired when sulfamoxole is combined with trimethoprim.